S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48

Axon Enterprise Stock Forecast, Price & News

+0.35 (+0.26%)
(As of 01/19/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
484,314 shs
Average Volume
483,514 shs
Market Capitalization
$9.08 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive AXON News and Ratings via Email

Sign-up to receive the latest news and ratings for Axon Enterprise and its competitors with MarketBeat's FREE daily newsletter.

Axon Enterprise logo

About Axon Enterprise

Axon Enterprise, Inc. engages in the development, manufacturing, and sale of conducted electrical weapons for personal defense. It operates through the TASER Weapons and Software and Sensors segments. The TASER Weapons segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.


See More Headlines

Industry, Sector and Symbol

Ordnance & accessories, except vehicles & guided missiles
Systems Software
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$681 million
Cash Flow
$0.33 per share
Book Value
$15.36 per share


Net Income
$-1.72 million
Pretax Margin




Free Float
Market Cap
$9.08 billion

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.37 out of 5 stars

Industrial Products Sector

96th out of 248 stocks

Ordnance & Accessories, Except Vehicles & Guided Missiles Industry

4th out of 8 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -

Axon Enterprise (NASDAQ:AXON) Frequently Asked Questions

Is Axon Enterprise a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axon Enterprise in the last year. There are currently 1 hold rating, 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Axon Enterprise stock.
View analyst ratings for Axon Enterprise
or view top-rated stocks.

When is Axon Enterprise's next earnings date?

Axon Enterprise is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Axon Enterprise

How were Axon Enterprise's earnings last quarter?

Axon Enterprise, Inc. (NASDAQ:AXON) released its earnings results on Monday, November, 15th. The biotechnology company reported $1.17 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.26 by $0.91. The biotechnology company earned $231.99 million during the quarter, compared to analyst estimates of $201.11 million. Axon Enterprise had a negative net margin of 2.37% and a negative trailing twelve-month return on equity of 2.26%. Axon Enterprise's quarterly revenue was up 39.4% on a year-over-year basis. During the same period last year, the business posted ($0.01) EPS.
View Axon Enterprise's earnings history

What guidance has Axon Enterprise issued on next quarter's earnings?

Axon Enterprise issued an update on its FY 2021 earnings guidance on Monday, December, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $850 million-$850 million, compared to the consensus revenue estimate of $843.58 million.

What price target have analysts set for AXON?

9 brokerages have issued 1-year target prices for Axon Enterprise's shares. Their forecasts range from $170.00 to $250.00. On average, they anticipate Axon Enterprise's stock price to reach $206.13 in the next year. This suggests a possible upside of 55.5% from the stock's current price.
View analysts' price targets for Axon Enterprise
or view top-rated stocks among Wall Street analysts.

Who are Axon Enterprise's key executives?

Axon Enterprise's management team includes the following people:

Who are some of Axon Enterprise's key competitors?

What other stocks do shareholders of Axon Enterprise own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axon Enterprise investors own include Novavax (NVAX), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), (CGC), Micron Technology (MU), TherapeuticsMD (TXMD), ACADIA Pharmaceuticals (ACAD), bluebird bio (BLUE) and Arena Pharmaceuticals (ARNA).

When did Axon Enterprise IPO?

(AXON) raised $251 million in an IPO on Thursday, June 11th 2015. The company issued 17,900,000 shares at a price of $13.00-$15.00 per share. Jefferies, Evercore ISI and RBC Capital Markets served as the underwriters for the IPO and JMP Securities and Baird were co-managers.

What is Axon Enterprise's stock symbol?

Axon Enterprise trades on the NASDAQ under the ticker symbol "AXON."

Who are Axon Enterprise's major shareholders?

Axon Enterprise's stock is owned by a variety of retail and institutional investors. Top institutional investors include Louisiana State Employees Retirement System (0.02%), LRT Capital Management LLC (0.01%), State of Alaska Department of Revenue (0.01%), Wedbush Securities Inc. (0.01%), Crossmark Global Holdings Inc. (0.01%) and Juncture Wealth Strategies LLC (0.01%). Company insiders that own Axon Enterprise stock include Adriane M Brown, Caitlin Elizabeth Kalinowski, Hadi Partovi, Jawad A Ahsan, Jeffrey C Kunins, Joshua Isner, Julie A Cullivan, Luke Larson, Matthew R Mcbrady, Matthew R Mcbrady and Patrick W Smith.
View institutional ownership trends for Axon Enterprise

Which institutional investors are selling Axon Enterprise stock?

AXON stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Crossmark Global Holdings Inc., Cutler Group LP, and Wedbush Securities Inc.. Company insiders that have sold Axon Enterprise company stock in the last year include Jawad A Ahsan, Jeffrey C Kunins, Joshua Isner, Julie A Cullivan, Luke Larson, Matthew R Mcbrady, and Patrick W Smith.
View insider buying and selling activity for Axon Enterprise
or view top insider-selling stocks.

Which institutional investors are buying Axon Enterprise stock?

AXON stock was bought by a variety of institutional investors in the last quarter, including LRT Capital Management LLC, Harbour Capital Advisors LLC, Pendal Group Ltd, YHB Investment Advisors Inc., Diversified Trust Co, Juncture Wealth Strategies LLC, Koshinski Asset Management Inc., and Stratos Wealth Partners LTD.. Company insiders that have bought Axon Enterprise stock in the last two years include Adriane M Brown, Caitlin Elizabeth Kalinowski, and Hadi Partovi.
View insider buying and selling activity for Axon Enterprise
or or view top insider-buying stocks.

How do I buy shares of Axon Enterprise?

Shares of AXON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Axon Enterprise's stock price today?

One share of AXON stock can currently be purchased for approximately $132.55.

How much money does Axon Enterprise make?

Axon Enterprise has a market capitalization of $9.08 billion and generates $681 million in revenue each year. The biotechnology company earns $-1.72 million in net income (profit) each year or ($0.40) on an earnings per share basis.

How many employees does Axon Enterprise have?

Axon Enterprise employs 2,548 workers across the globe.

What is Axon Enterprise's official website?

The official website for Axon Enterprise is www.axovant.com.

Where are Axon Enterprise's headquarters?

Axon Enterprise is headquartered at 20-22 BEDFORD ROW, LONDON X0, WC1R 4JS.

How can I contact Axon Enterprise?

Axon Enterprise's mailing address is 20-22 BEDFORD ROW, LONDON X0, WC1R 4JS. The biotechnology company can be reached via phone at (480) 991-0797, via email at [email protected], or via fax at 480-991-0791.

This page was last updated on 1/20/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.